On December 20, 2024, the US Court of Appeals for the Federal Circuit released its opinion in Teva Branded Pharm. Prods. R&D, Inc. v. Amneal ...

Teva loses US appeal to keep inhaler patents on FDA protected drug list December 20, 2024 Amneal Pharmaceuticals has sued Colorado in an effort to block a state law requiring it to provide free ...

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog.

BRIDGEWATER, N.J., November 21, 2024--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, today ...

The subsidiary seeks damages and injunctions. Vandana Singh Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts Amneal Pharmaceuticals Q3 sales rose 13% to $702.47 ...

BRIDGEWATER, N.J., November 21, 2024--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist BRIDGEWATER ...

In an order posted by the U.S. Court of Appeals for the Federal Circuit, the court affirmed a win for Amneal Pharmaceuticals (AMRX) in a decision that would remove patents related to Teva ...